Sofinnova Partners

Founded 1972

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 233
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 149
Rounds per year 4.76
Lead investments 83
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.39
Exits 54
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

Sofinnova Partners appeared to be the VC, which was created in 1972. The company was established in Europe in France. The leading representative office of defined VC is situated in the Paris.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. We can highlight the next thriving fund investment areas, such as Health Care, Medical Device. Among the most popular portfolio startups of the fund, we may highlight Addex Therapeutics, DBV Technologies, MedDay. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

Besides them, we counted 11 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Sofinnova Partners, startups are often financed by Gimv, Idinvest Partners, Bpifrance. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Idinvest Partners, Auriga Partners. In the next rounds fund is usually obtained by Gimv, Andera Partners, Venrock.

This Sofinnova Partners works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2010. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 7-12 deals every year. The average startup value when the investment from Sofinnova Partners is 10-50 millions dollars. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

TISSIUM

Biotechnology
Health Care
Medical Device
$59M31 Aug 2021 Paris, Ile-de-France, France

Protera

AgTech
Biotechnology
Genetics
Health Care
Life Science
$10M28 Jul 2021 Sunnyvale, California, United States

Artios Pharma

Biopharma
Biotechnology
Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Comet Biorefining

Agriculture
Biotechnology
Business Development
Professional Services
$22M13 Jul 2021 London, Ontario, Canada

Micropep Technologies

Agriculture
Biotechnology
Chemical
Lead Generation
$10M08 Jul 2021 France, Auvergne-Rhône-Alpes, France

Alia Therapeutics

Biotechnology
Therapeutics
30 Jun 2021 Trento, Trentino-Alto Adige, Italy

Borea Therapeutics

Biotechnology
Therapeutics
29 Jun 2021 Milan, Lombardy, Italy

Mnemo Therapeutics

Biotechnology
$88M16 Jun 2021 Paris, Ile-de-France, France

Mainstay Medical

Biotechnology
Emergency Medicine
Health Care
Medical
Medical Device
$108M16 Feb 2021 Dublin, County Dublin, Ireland
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Tissium Raises €50M in Series C Financing

– Tissium is a medtech company developing biomorphic programmable polymers for tissue reconstruction.
– Company raised €50M in Series C financing.
– The round was led by Cathay Health, affiliated to global investment firm Cathay Capital, with participation from existing shareholders Sofinnova Partners, and others.
– The company intends to use the funds to continue to execute on its development plan, up to the commercialization of its nerve repair, hernia repair and cardiovascular sealant products.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sofinnova Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: